Neuropsychiatric toxicity associated with cytokine therapies

Psychosomatics

Volumn 40, Issue 5, 1999, Pages 428-435

  Lerner, Darin M ^a   Stoudemire, Alan ^b   Rosenstein, Donald L ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HALOPERIDOL; INTERLEUKIN 1; INTERLEUKIN 2; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD TOXICITY; CARDIOTOXICITY; DEGENERATIVE DISEASE; DELIRIUM; DEPRESSION; ENDOCRINE DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOMODULATION; INFECTION; LUNG DISEASE; MALIGNANT NEOPLASTIC DISEASE; NEPHROTOXICITY; NEUROPATHOLOGY; NEUROTOXICITY; PATHOPHYSIOLOGY;

EID: 0032838941     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0033-3182(99)71208-9     Document Type: Article

References (29)

1. Hanisch UW, Quirion R: Interleukin-2 as a neuroregulatory cytokine. Brain Research Reviews 1996; 21:246-284
2. Rosenberg SA, Yang JC, Topalian SL, et al: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271:907-913
3. Saris SC PN, Rosenberg SA: The effect of intravenous interleukin-2 on brain water content. J Neurosurg 1989; 71:169-174
4. Denicoff KD, Durkin TM, Lotze MT, et al: The neuroendocrine effects of interleukin 2 treament. J Clin Endocrinol Metab 1989; 69:402-410
5. Vial T, Descotes J: Clinical toxicity of interleukin-2. Drug Saf 1992; 7:417-433
6. Kammula US, White DE, Rosenberg SA: Trends in the safety of high-dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 1998; 83:797-805
7. Palmer PA, Atzpodien J, Philip T, et al: Comparison of two modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma. Cancer Biotherapy 1993; 8:123-135
8. Denicoff KD, Rubinow DR, Papa MZ, et al: The neuropsychiatric effects of treatment with interleukin 2 and lymphokine-activated killer cells. Ann Intern Med 1987; 107:293-300
9. Karp BI, Yang JC, Khorsand M, et al: Multiple cerebral lesions complicating therapy with interleukin 2. Neurology 1996; 47:417-424
10. Pace A, Pietrangeli A, Bove L, et al: Neurotoxicity of antitumoral IL-2 therapy: evoked cognitive potentials and brain mapping. Italian Journal of Neuroscience 1994; 15:341-346
11. Meyers CA, Valentine AD: Neurological and psychiatric adverse effects of immunological therapy. CNS Drugs 1995; 3:56-68
12. Sipahimalani A, Masand PS: Use of respiridone in delirium. Ann Clin Psychiatry 1997; 9:105-106
13. Sipahimalani A, Masand PS: Olanzapine in the treatment of delirium. Psychosomatics 1998; 39:422-430
14. Triozzi PL, Kinney P, Rinehart JJ: Central nervous system toxicity of biological response modifiers. Ann N Y Acad Sci 1990; 594:347-354
15. Licinio J, Kling MA, Hauser P: Cytokines and brain function: relevance to interferon alpha-induced mood and cognitive changes. Semin Oncol 1998; 25:30-38
16. Blalock JE, Smith EM: Human leukocyte interferon: structural and biological relatedness to adrenocorticotrophic hormone and endorphins. Proc Nat Acad Sci USA 1980; 77:5972-5974
17. Valentine AD, Meyers CA, Kling MA, et al: Mood and cognitive side effects of interferon alpha therapy. Semin Oncol 1998; 25:39-47
18. Adams ML, Cicero TJ: Alcohol intoxication and withdrawal: the role of nitric oxide. Alcohol 1998; 16:153-158
19. Renault PF, Hoofnagle JH, Park Y, et al: Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987; 147:1577-1580
20. Vial T, Descotes J: Clinical toxicity of the interferons. Drug Saf 1994; 10:115-150
21. Pardo M, Marriott E, Moliner MC, et al: Risks and benefits of interferon-alfa in the treatment of hepatitis. Drug Saf 1995; 13:304-316
22. Lindsay KL, Davis GL, Schiff ER, et al: Group HIT: response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatology 1996; 24:1034-1040
23. Strite D, Valentine AD, Meyers CA: Manic episodes in two patients treated with interferon alpha. J Neuropsychiatry Clin Neurosci 1997; 9:273-276
24. Pavol MA, Meyers CA, Rexer JL, et al: Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology 1995; 45:947-950
25. Poutianien E, Hokkanen M-LN, Farkkila M: Reversible cognitive decline during high-alfa interferon treatment. Pharmacol Biochem Behav 1994; 47:901-905
26. Forman AD: Neurologic complications of cytokine therapy. Oncology 1994; 8:105-110
27. Pariante CM, Orrú MG, Baita A, Farci MG, Carpiniello B: Treatment with interferon-α in patients with chronic hepatitis and mood or anxiety disorders. The Lancet 1999; 354:131-132
28. Renault PF, Hoofnagle JH: Side effects of alpha interferon. Semin Liver Dis 1989; 9:273-277
29. Janssen HLA, Brouwer JT, van der Mast RC, et al: Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994; 21:241-243